Facial Dermatitis in Male Patients Referred for Patch Testing: Retrospective Analysis of North American Contact Dermatitis Group Data, 1994 to 2016.


Journal

JAMA dermatology
ISSN: 2168-6084
Titre abrégé: JAMA Dermatol
Pays: United States
ID NLM: 101589530

Informations de publication

Date de publication:
01 01 2020
Historique:
pubmed: 28 11 2019
medline: 6 11 2020
entrez: 28 11 2019
Statut: ppublish

Résumé

Facial dermatitis in women is well characterized. However, recent shifts in the men's grooming industry may have important implications for male facial dermatitis. To characterize male patients with facial dermatitis. A 22-year retrospective cross-sectional analysis (1994-2016) of North American Contact Dermatitis Group (NACDG) data, including 50 507 patients who underwent patch testing by a group of dermatology board-certified patch test experts at multiple centers was carried out. Facial dermatitis was defined as involvement of the eyes, eyelids, lips, nose, or face (not otherwise specified). The main outcome was to compare characteristics (including demographics and allergens) between male patients with facial dermatitis (MFD) and those without facial dermatitis (MNoFD) using statistical analysis (relative risk, CIs). Secondary outcomes included sources of allergic and irritant contact dermatitis and, for occupationally related cases, specific occupations and industries in MFD. Overall, 1332 male patients (8.0%) were included in the MFD group and 13 732 male patients (82.0%) were included in MNoFD. The mean (SD) age of participants was 47 (17.2) years in the MFD group and 50 (17.6) years in the MNoFD group. The most common facial sites were face (not otherwise specified, 817 [48.9%]), eyelids (392 [23.5%]), and lips (210 [12.6%]). Participants in the MFD group were significantly younger than MNoFD (mean age, 47 vs 50 years; P < .001). Those in the MFD group were less likely to be white (relative risk [RR], 0.92; 95% CI, -0.90 to 0.95) or have occupationally related skin disease (RR, 0.49; 95% CI, -0.42 to 0.58; P < .001) than MNoFD. The most common allergens that were associated with clinically relevant reactions among MFD included methylisothiazolinone (n = 113; 9.9%), fragrance mix I (n = 27; 8.5%), and balsam of Peru (n = 90; 6.8%). Compared with MNoFD, MFD were more likely to react to use of dimethylaminopropylamine (RR, 2.49; 95% CI, -1.42 to 4.37]) and paraphenylenediamine (RR, 1.43; 95% CI, -1.00 to 2.04; P < .001). Overall, 60.5% of NACDG allergen sources were personal care products. Although many allergens were similar in both groups, MFD were more likely to react to use of dimethylaminopropylamine and paraphenylenediamine, presumably owing to their higher prevalence in hair products. Most sources of allergic and irritant contact dermatitis in MFD were personal care products. This study provides insight into the risks and exposures of the increasing number of grooming products used by male dermatology patients. This will enable clinicians to better identify male patients who would benefit from patch testing and treat those with facial dermatitis.

Identifiants

pubmed: 31774459
pii: 2755535
doi: 10.1001/jamadermatol.2019.3531
pmc: PMC6902109
doi:

Substances chimiques

Allergens 0
Cosmetics 0
Metalloporphyrins 0
factor F430 73145-13-8

Types de publication

Journal Article Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

79-84

Commentaires et corrections

Type : CommentIn

Références

Am J Contact Dermat. 1999 Sep;10(3):153-6
pubmed: 10444108
Dermatitis. 2008 Jul-Aug;19(4):202-8
pubmed: 18674455
J Drugs Dermatol. 2018 Mar 1;17(3):301-306
pubmed: 29537448
Food Chem Toxicol. 2013 May;55:8-17
pubmed: 23174517
Dermatitis. 2007 Jun;18(2):78-81
pubmed: 17498412
Aesthet Surg J. 2015 Nov;35(8):1007-13
pubmed: 26508650
Dermatitis. 2018 Nov/Dec;29(6):297-309
pubmed: 30422882
Dermatitis. 2017 May/Jun;28(3):183-194
pubmed: 28394773
Dermatitis. 2017 Jan/Feb;28(1):81-87
pubmed: 28098722
Clin Dermatol. 1993 Apr-Jun;11(2):289-95
pubmed: 8348443
Dermatitis. 2009 Mar-Apr;20(2):106-10
pubmed: 19426617
Contact Dermatitis. 2000 Aug;43(2):90-4
pubmed: 10945747

Auteurs

Erin M Warshaw (EM)

Department of Dermatology, Minneapolis Veterans Affairs Medical Center, Minneapolis, Minnesota.
Department of Dermatology, University of Minnesota, Minneapolis.

Jamie P Schlarbaum (JP)

Department of Dermatology, Minneapolis Veterans Affairs Medical Center, Minneapolis, Minnesota.
University of Minnesota Medical School, Minneapolis.

Howard I Maibach (HI)

Department of Dermatology, University of California, San Francisco.

Jonathan I Silverberg (JI)

Department of Dermatology, The George Washington University, Washington, DC.

James S Taylor (JS)

Department of Dermatology, Cleveland Clinic, Cleveland, Ohio.

Amber R Atwater (AR)

Department of Dermatology, Duke University, Durham, North Carolina.

Margo J Reeder (MJ)

Department of Dermatology, University of Wisconsin Medical School, Madison.

Joel G DeKoven (JG)

Division of Dermatology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada.

Melanie D Pratt (MD)

Division of Dermatology, University of Ottawa, Ottawa, Ontario, Canada.

Vincent A DeLeo (VA)

Department of Dermatology, Keck School of Medicine, Los Angeles, California.

Kathryn A Zug (KA)

Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire.

Anthony F Fransway (AF)

Associates in Dermatology, Fort Myers, Florida.

Donald V Belsito (DV)

Department of Dermatology, Columbia University, New York, New York.

Toby Mathias (T)

Department of Dermatology, University of Cincinnati, Cincinnati, Ohio.

Joseph F Fowler (JF)

University of Louisville, Louisville, Kentucky.

James G Marks (JG)

Department of Dermatology, Pennsylvania State University, State College, Pennsylvania.

Denis Sasseville (D)

Division of Dermatology, Royal Victoria Hospital, McGill University, Montreal, Quebec, Canada.

Matthew J Zirwas (MJ)

Department of Dermatology, Ohio State University, Columbus.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH